Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
Economy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Last updated: April 23, 2025 6:12 pm
Share
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
SHARE

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that has been in the spotlight recently as one of the cheap NASDAQ stocks to buy according to hedge funds. With a forward P/E ratio of 13.24 and 74 hedge fund holders, Gilead is making waves in the industry.

In a recent interview on CNBC, Dan Ives, Head of Global Tech Research at Wedbush Securities, discussed the current state of the tech sector, highlighting the potential for major volatility ahead. The uncertainty in the tech industry has been exacerbated by escalating tariffs on China, reaching as high as 125%. This has forced companies to rethink their supply chains and has resulted in a noticeable pause in tech spending.

Despite the challenges, Ives has not downgraded tech stocks, emphasizing the potential for clear winners to emerge from the current turmoil. He predicts that Street estimates are likely to see earnings cuts of about 10% across internet and big tech companies, reflecting the broader pullback in spending and ongoing volatility.

Gilead Sciences has seen success in its HIV franchise, with sales reaching $19.6 billion in 2024. Key products like Biktarvy and Descovy have contributed to this growth, solidifying Gilead’s position in the market. While the company expects some temporary challenges in 2025 due to Medicare Part D reform, the underlying HIV business remains strong.

In a recent investor letter, ClearBridge Value Strategy praised Gilead’s performance, citing strong fourth-quarter earnings growth and positive reception to its new treatments. Overall, Gilead ranks 9th on the list of cheap NASDAQ stocks to buy according to hedge funds.

See also  Why Oracle Could Be the Next Stock to Join the $1 Trillion Club

While Gilead shows promise, there are other opportunities in the market, particularly in AI stocks. These stocks have the potential to deliver high returns in a shorter time frame. If you’re looking for an AI stock with significant growth potential, consider exploring the cheapest AI stock highlighted in our report.

In conclusion, Gilead Sciences is positioned as a strong contender in the biopharmaceutical industry, with a solid track record and promising future prospects. However, investors should also consider exploring opportunities in AI stocks for potentially higher returns. Stay informed and make informed investment decisions based on the latest market trends and opportunities.

TAGGED:BuyCheapfundsGILDGileadhedgeNasdaqSciencesStock
Share This Article
Twitter Email Copy Link Print
Previous Article Can climate science attribute economic damage to major polluters? Can climate science attribute economic damage to major polluters?
Next Article How Legal Aid’s pro-crime push puts all of us in danger How Legal Aid’s pro-crime push puts all of us in danger
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Creator on Saxton’s Death, Watergate Tapes

The first season of the 70s crime drama "Duster" on Max came to a thrilling…

July 3, 2025

In a Rare Daytime Appearance, Flying Foxes Keep Cool in an Indian River — Colossal

Photographer Hardik Shelat recently embarked on an expedition in Gujarat, India, where he witnessed a…

June 4, 2025

Citadel Securities profits jump 70% on surge in trading revenues

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite…

May 27, 2025

How To Make Less Trash the Simple Way

What exactly does it mean to adopt a zero waste lifestyle? Is it feasible to…

October 7, 2025

Three Generations Grow Closer Over Traditional Vietnamese Cuisine in ‘Spring Roll Dream’ — Colossal

"Spring Roll Dream" is a poignant stop-motion short film that delves into the complexities of…

December 6, 2024

You Might Also Like

29 truck carrier files Chapter 11
Economy

29 truck carrier files Chapter 11

October 31, 2025
Trust Government Statistics, Not Government
Economy

Trust Government Statistics, Not Government

October 31, 2025
Jefferies Raises BP Price Target to 420 GBp, Maintains Hold Rating
Economy

Jefferies Raises BP Price Target to 420 GBp, Maintains Hold Rating

October 31, 2025
Dan Ives’ AI ETF Hits B in Assets Just Five Months After Launch
Economy

Dan Ives’ AI ETF Hits $1B in Assets Just Five Months After Launch

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?